Miramistin Solution for topical application, 0.01%, 50 ml

pharmachologic effect

Miramistin has a wide spectrum of antimicrobial activity, including hospital strains that are resistant to antibiotics.

The drug has a pronounced bactericidal effect against gram-positive (Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, etc.), gram-negative (Pseudomonas aeruginosa, Escherichia coli, Klebsiella spp., Etc.), aerobic and anaerobic bacteria, determined microbial associations, including hospital strains with multidrug resistance to antibiotics.

It has an antifungal effect on ascomycetes of the genus Aspergillus and genus Penicillium, yeast (Rhodotorula rubra, Torulopsis gabrata, etc.) and yeast-like fungi (Candida albicans, Candida tropicalis, Candida krusei, Pityrosporum orbiculare (Malassezia), furfurfurf dermatophytes (Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton schoenleini, Trichophyton violacent, Epidermophyton Kaufman-Wolf, Epidermophyton floccosum, Microsporum gypseum, Microsporum canis and other pathogenic fungi, etc.), and other pathogenic fungi , including fungal microflora with resistance to chemotherapy drugs.

It has an antiviral effect, is active against complex viruses (herpes viruses, human immunodeficiency virus, etc.).

Miramistin acts on the causative agents of sexually transmitted diseases (Chlamydia spp., Treponema spp., Trichomonas vaginalis, Neisseria gonorrhoeae, etc.).

Effectively prevents infection of wounds and burns.

It activates the regeneration processes.

Stimulates protective reactions at the site of application, by activating the absorption and digestion functions of phagocytes, potentiates the activity of the monocytic-macrophage system.

It has a pronounced hyperosmolar activity, as a result of which it relieves wound and perifocal inflammation, absorbs purulent exudate, contributing to the formation of a dry scab.

Does not damage granulation and viable skin cells, does not inhibit marginal epithelization.

Does not possess local irritating effect and allergenic properties.

Pharmacokinetics

When applied topically, miramistin does not have the ability to be absorbed through the skin and mucous membranes.

Indications

Surgery, traumatology: prevention of suppuration and treatment of purulent wounds.

Treatment of purulent-inflammatory processes of the musculoskeletal system.

Obstetrics, gynecology: prevention and treatment of suppuration of postpartum injuries, perineal and vaginal wounds, postpartum infections, inflammatory diseases (vulvovaginitis, endometritis).

Combustiology: treatment of superficial and deep burns of II and IIIA degrees, preparation of burn wounds for dermatoplasty.

Dermatology, venereology: treatment and prevention of pyoderma and dermatomycosis, candidiasis of the skin and mucous membranes, mycoses of the feet.

Individual prevention of sexually transmitted diseases (including syphilis, gonorrhea, chlamydia, trichomoniasis, genital herpes, genital candidiasis).

Urology: complex treatment of acute and chronic urethritis and urethroprostatitis of a specific (chlamydia, trichomoniasis, gonorrhea) and non-specific nature.

Dentistry: treatment and prevention of infectious and inflammatory diseases of the oral cavity: stomatitis, gingivitis, periodontitis, periodontitis.

Hygienic treatment of removable dentures.

Otorhinolaryngology: complex treatment of acute and chronic otitis media, sinusitis, tonsillitis, laryngitis, pharyngitis.

In children aged 3 to 14 years, it is used for the complex treatment of acute pharyngitis and / or exacerbation of chronic tonsillitis.

Contraindications

Individual intolerance to the drug.

Side effects

In some cases, a slight burning sensation may occur at the injection site, which disappears on its own after 15–20 s and does not require discontinuation of the drug.

Allergic reactions.

Interaction

At the same time

Name ENG

MYRAMISTIN

Clinical and pharmacological group

Antiseptic for external use

ATX code

Other antimicrobials for external use

Dosage

0.01% x 50ml

Structure

Active ingredient: benzyldimethyl [3- (myristoylamino) propyl] ammonium chloride monohydrate (in terms of anhydrous substance) 0.1 g

...

Excipient: purified water - up to 1 liter

Indications

Surgery, traumatology: prevention of suppuration and treatment of purulent wounds.

Treatment of purulent-inflammatory processes of the musculoskeletal system.

Obstetrics, gynecology: prevention and treatment of suppuration of postpartum injuries, perineal and vaginal wounds, postpartum infections, inflammatory diseases (vulvovaginitis, endometritis).

Combustiology: treatment of superficial and deep burns of II and IIIA degrees, preparation of burn wounds for dermatoplasty.

Dermatology, venereology: treatment and prevention of pyoderma and dermatomycosis, candidiasis of the skin and mucous membranes, mycoses of the feet.

Individual prevention of sexually transmitted diseases (including syphilis, gonorrhea, chlamydia, trichomoniasis, genital herpes, genital candidiasis).

Urology: complex treatment of acute and chronic urethritis and urethroprostatitis of a specific (chlamydia, trichomoniasis, gonorrhea) and non-specific nature.

Dentistry: treatment and prevention of infectious and inflammatory diseases of the oral cavity: stomatitis, gingivitis, periodontitis, periodontitis.

Hygienic treatment of removable dentures.

Otorhinolaryngology: complex treatment of acute and chronic otitis media, sinusitis, tonsillitis, laryngitis, pharyngitis.

In children aged 3 to 14 years, it is used for the complex treatment of acute pharyngitis and / or exacerbation of chronic tonsillitis.

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 3 years

Contraindications

Hypersensitivity to the drug.

INN / Active ingredient

Benzyldimethyl 3- (Myristoylamino) Propylammonium Chloride Monohydrate

Specifications

Category

Genitourinary tract infections

Scope of the drug

General

Release form

Solution

Manufacturer country

Russia

Package quantity, pcs

one

Vacation conditions

Without recipe

Brand name

Infamed

Components

urological applicator

The amount of the dosage form in the primary package

50 ml

Primary packaging type

Bottle

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Antiseptic

Anatomical and therapeutic characteristics

D08AJ Quaternary ammonium compounds

Dosage form

Topical solution

Expiration date in days

1095

Package weight, g

80

Mode of application

:

Locally. The drug is ready for use. < br> Surgery, traumatology, combustiology. For prophylactic and therapeutic purposes, the surface of wounds and burns is irrigated, wounds and fistulous passages are loosely tamponed, gauze tampons moistened with the drug are fixed. The treatment procedure is repeated 2-3 times a day for 3-5 days. A highly effective method of active drainage of wounds and cavities with a daily consumption of up to 1 liter of the drug. Film Obstetrics, Gynecology. In order to prevent postpartum infection, it is used in the form of vaginal irrigation before childbirth (5-7 days), during childbirth after each vaginal examination and in the postpartum period, 50 ml of the drug in the form of a tampon with an exposure of 2 hours for 5 days. When women are delivered by cesarean section, immediately before the operation, the vagina is treated, during the operation - the uterine cavity and an incision on it,and in the postoperative period, tampons moistened with the drug are introduced into the vagina with an exposure of 2 hours for 7 days. Treatment of inflammatory diseases is carried out in a course of 2 weeks by intravaginal administration of tampons with the drug, as well as by the method of drug electrophoresis. Film Venereology. For the prevention of sexually transmitted diseases, the drug is effective if it is used no later than 2 hours after intercourse. Introduce the contents of the vial with the urological applicator into the urethra for 2–3 minutes: for men - 2–3 ml, for women - 1–2 ml, and into the vagina - 5–10 ml. Treat the skin of the inner surfaces of the thighs, pubis, genitals. After the procedure, it is recommended not to urinate for 2 hours. < br> Urology.In the complex treatment of urethritis and urethroprostatitis, 2-3 ml of the drug is injected into the urethra 1-2 times a day, the course is 10 days. < br> Otorhinolaryngology. With purulent sinusitis - during puncture, the maxillary sinus is washed with a sufficient amount of the drug. < br> Tonsillitis, pharyngitis and laryngitis are treated by gargling and / or irrigation with a spray nozzle, 3-4 times pressing 3-4 times a day. The amount of the preparation for 1 rinse is 10-15 ml. Film At Children. In case of acute pharyngitis and / or exacerbation of chronic tonsillitis, irrigation of the pharynx is carried out using a spray nozzle. Children aged 3–6 years - 3-5 ml for one irrigation (single press on the head of the spray nozzle) 3-4 times a day 7-14 years old - 5-7 ml for one irrigation (double pressing) 3-4 times a day over 14 years old - 10-15 ml per one irrigation (3-4 times pressing) 3-4 times a day. The duration of therapy is from 4 to 10 days, depending on the timing of the onset of remission. Film Dentistry. For stomatitis, gingivitis, periodontitis, it is recommended to rinse the mouth with 10-15 ml of the drug 3-4 times a day. < br>

Dosage (volume) of the substance in the preparation

:

Benzyldimethyl [3- (Myristoylamino) Propyl] Ammonium Chloride Monohydrate (Calculated As Anhydrous Substance) 0.1 G

Information on technical characteristics, delivery set, country of manufacture